TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03063476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-13 labeled Lysine
Description: Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
Study: NCT06326073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Treatment
Description: Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
Study: NCT01856621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler and charcoal
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler
Description: 2 inhalations as a single dose
Study: NCT04294771

Intervention type: DRUG
Intervention: ICI
Description: Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
Study: NCT02260726

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT00758641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-PRP Injection
Description: L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: kenacort 40 mg/ml triamcinolon acetonide
Study: NCT04570189

Intervention type: DEVICE
Intervention: Auscul-X
Description: The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously

Intervention type: DEVICE
Intervention: Auscul-X
Description: The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
Study: NCT04463004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavrilimumab
Description: Treatment infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo infusion
Study: NCT01531413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen Insufflation
Description: At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
Study: NCT03500809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aqueous release of the wound
Description: 1. Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~2. This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye.
Study: NCT01020435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Spinal Manipulation
Description: The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
Study: NCT03132571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Study: NCT03467672

Intervention type: OTHER
Intervention: Diagnosis of bacterial infection
Description: use of eosinopenia in the diagnosis of bacterial infection
Study: NCT03132571

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo taken once daily for the course of the study (16 week)
Study: NCT00952640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A
Description: high dose vitamin A, 200.000 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: high dose vitamin A, 200.000 IU
Study: NCT03606863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative peripheral parenteral nutrition
Study: NCT00458094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention with peer support (PA+PS)
Description: Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity intervention without peer support (PA)
Description: Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
Study: NCT03733951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia.
Study: NCT01450774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6µg
Description: fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Study: NCT04105998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 10 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 10 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01450774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Description: free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Study: NCT03507699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Liver radiation therapy
Description: 21 Gy in three fractions to one liver metastasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: administered IV at a dose of 3mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: administered IV at a dose of 3mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: administered IV at a dose of 1mg/kg every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: administered IV at a dose of 1mg/kg every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
Study: NCT05790759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait
Description: Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
Study: NCT04495153

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Aglatimagene besadenovec
Description: Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
Study: NCT02643589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
Study: NCT02418286

Intervention type: OTHER
Intervention: expose to any drugs or procedures based on traditional Korean medicine theory
Description: There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
Study: NCT03032965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
Study: NCT03669224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 2 % chlorhexidine gluconate. This group will be compared with no intervention group.
Study: NCT04414774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GG-Suicide-Ideation
Description: GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GG-Suicide-Ideation
Description: GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
Study: NCT02765763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Minute Reveal Masque

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24/7 Barrier Repair Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8-in-1 BioSerum

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Null Formula 2-Minute Reveal Masque

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Null Formula 24/7 Barrier Repair Cream

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Null Formula 8-in-1 BioSerum
Study: NCT03101176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: The ultrasound contrast agent used for the CEUS specific ultrasound mode
Study: NCT05147012

Intervention type: OTHER
Intervention: Data collected
Description: The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients.
Study: NCT01601340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HQK-1001
Description: HQK-1001 tablets, twice daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, twice daily for 48 weeks
Study: NCT01537939

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASUKI Step Worksite Pedometer Intervention
Description: The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
Study: NCT05298826

Intervention type: DRUG
Intervention: recombinant factor VIIa
Description: using recombinant factor VIIa

Intervention type: DRUG
Intervention: recombinant factor VIIa
Description: using recombinant factor VIIa
Study: NCT03032965

Intervention type: DRUG
Group type: OTHER
Intervention: Isoproterenol
Description: Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
Study: NCT04048226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
Study: NCT03010683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
Study: NCT02876718

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
Study: NCT03980535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study: NCT02216097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845
Description: 4mg PF-04457845 tablet taken once daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet taken once daily for 7 days.
Study: NCT01406574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121
Description: Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121 phase2
Description: Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
Study: NCT04214197

Intervention type: DRUG
Group type: OTHER
Intervention: Crisaborole 2% Top Oint
Description: Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
Study: NCT03672591

Intervention type: OTHER
Intervention: Renal clearance examination
Description: Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol

Intervention type: OTHER
Intervention: Renal clearance examination
Description: Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
Study: NCT02103855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept